Shots:

• The US FDA has granted FT designation vutrisiran for treating polyneuropathy of hATTR amyloidosis in adults. The designation allows Alnylam to submit NDA for vutrisiran
• The P-I study assessing Vutrisiran (quarterly dosing with low-volume- SC) demonstrated a reduction in the burden of care for the disease. The safety & efficacy of the therapy are being evaluated ongoing HELIOS-A and HELIOS-B P-III clinical studies with the anticipated P-III HELIOS-A results in H1’21
• Vutrisiran (SC) is an investigational- RNAi therapeutic in development for the treatment of ATTR amyloidosis- which encompasses both hereditary (hATTR) and wild-type (wtATTR) amyloidosis

Click here ­to­ read full press release/ article | Ref: Alnylam | Image: Alnylam